NCT06954116View on ClinicalTrials.gov

Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

April 1, 2029

Conditions
Resectable Hepatocellular Carcinoma With High Risk of Recurrence
Interventions
DRUG

Iparomlimab and Tuvonralimab (QL1706)

"Neoadjuvant phase: A single cycle of Iparomlimab and Tuvonralimab (7.5 mg/kg) will be administered within 1 week prior to surgery.~Adjuvant phase: Six cycles of Iparomlimab and Tuvonralimab (7.5 mg/kg, Q3W) will be initiated starting at 2 weeks postoperatively."

PROCEDURE

Partial hepatectomy

Will be performed at an appropriate interval following neoadjuvant therapy initiation.

Trial Locations (1)

430030

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
collaborator

Qilu Pharmaceutical Co., Ltd.

INDUSTRY

lead

Tongji Hospital

OTHER